Creating a Soluble Binder to Endothelin-1 Based on the Natural Ligand Binding Domains of the Endothelin-1 (G-Protein-Coupled) Receptor
Tóm tắt
Since its discovery in 1989, there has been extensive research on endothelin (ET)-1 physiology, as well as pathology. Accordingly, there is considerable research on the discovery of therapeutics based around ET-1, amongst which current treatment options include endothelin receptor antagonists. These target the ET-1 receptors, which are G-protein–coupled receptors (GPCRs). We have effectively developed a soluble form of a GPCR that binds to ligands, by constructing a fusion polypeptide of different endothelin receptor ligand binding domains. Phage experiments identified strong binders to ET-1. We then constructed Fc-fusions of the top binders and further binding assays revealed a KD of 21.2 nM for the Fc-ETtr1 construct and KD of 77.3 nM for the Fc-ETtr2 construct. These constructs are soluble and have the ability to bind and potentially sequester elevated ET-1 levels that are prevalent in different diseases. These results provide a novel approach to targeting GPCR–binding ligands, and thereby to contribute to a very important class of therapeutics.
Tài liệu tham khảo
Adachi M et al (1993) Functional domains of human endothelin receptor. J Cardiovasc Pharmacol 22(Suppl 8):S121–S124
Aurora R et al (1997) Local interactions in protein folding: lessons from the alpha-helix. J Biol Chem 272(3):1413–1416
Beck A, Reichert JM (2011) Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 3(5):415–416
Brazil M (2003) Setting a trap for cytokines. Nat Rev Drug Discov 2(2):90–90
Chaumais MC et al (2015) Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. Am J Cardiovasc Drugs 15(1):13–26
Dinarello CA (2003) Setting the cytokine trap for autoimmunity. Nat Med 9(1):20–22
Fiore G et al (2005) Endothelin-1 triggers placental oxidative stress pathways: putative role in preeclampsia. J Clin Endocrinol Metab 90(7):4205–4210
Gabbay E, Fraser J, McNeil K (2007) Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 3(6):887–900
George EM, Granger JP (2011) Endothelin: key mediator of hypertension in preeclampsia. Am J Hypertens 24(9):964–969
George RA, Heringa J (2002) An analysis of protein domain linkers: their classification and role in protein folding. Protein Eng 15(11):871–879
Hiley CR et al (1992) BQ-123, cyclo(-D-Trp-D-Asp-Pro-D-Val-Leu), is a non-competitive antagonist of the actions of endothelin-1 in SK-N-MC human neuroblastoma cells. Biochem Biophys Res Commun 184(1):504–510
Huovinen T et al (2013) Two ScFv antibody libraries derived from identical VL-VH framework with different binding site designs display distinct binding profiles. Protein Eng Des Sel 26(10):683–693
Jain A (2013) Endothelin-1-induced endoplasmic reticulum stress in disease. J Pharmacol Exp Ther 346(2):163–172
Jain A et al (2012) Endothelin-1 induces endoplasmic reticulum stress by activating the PLC-IP(3) pathway: implications for placental pathophysiology in preeclampsia. Am J Pathol 180(6):2309–2320
Karet F, Davenport A (1994) Endothelin and the human kidney: a potential target for new drugs. Nephrol Dial Transplant 9(5):4
Nelson J et al (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3(2):110–116
Orry AJ, Wallace BA (2000) Modeling and docking the endothelin G-protein-coupled receptor. Biophys J 79(6):3083–3094
Patel S et al (2013) Selection of a high-affinity WW domain against the extracellular region of VEGF receptor isoform-2 from a combinatorial library using CIS display. Protein Eng Des Sel 26(4):307–315
Schneider MP, Boesen EI, Pollock DM (2007) Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 47:731–759
Struck J, Morgenthaler NG, Bergmann A (2005) Proteolytic processing pattern of the endothelin-1 precursor in vivo. Peptides 26(12):2482–2486
Takasuka T et al (1992) Characterization of endothelin receptors ETA and ETB expressed in COS cells. J Biochem 112(3):396–400
Tam Tam KB et al (2011) Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance. Am J Obstet Gynecol 204(4):330e1–330e4